The company announced a new collaboration with the University of Alberta to develop drugs for use against SARS-Cov2

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a license agreement and extended a research collaboration with the University of Alberta, a leading Canadian research university, focused on identifying and testing broad-spectrum antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses.

The company announced a new collaboration with the University of Alberta to develop drugs for use against SARS-Cov2

https://www.globenewswire.com/news-release/2022/05/18/2445830/28908/en/Tonix-Pharmaceuticals-Extends-Research-Collaboration-with-the-University-of-Alberta-to-Develop-Antiviral-Drugs-Against-SARS-CoV-2.html

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a license agreement and extended a research collaboration with the University of Alberta, a leading Canadian research university, focused on identifying and testing broad-spectrum antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses.

https://finance.yahoo.com/news/indaptus-therapeutics-announces-fda-clearance-110000411.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.